| Name | Title | Contact Details |
|---|
MedFlight of Ohio is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sarah Bush Lincoln Health Center is a 129-bed, not-for-profit, regional hospital centrally located in East Central Illinois Coles County, and is the recipient of the 2011 Illinois Performance Excellence Gold Award for Achievement of Excellence, the highest performance honors in the state. Sarah Bush Lincoln is accredited by The Joint Commission, the nations oldest and largest standards-setting and accrediting body in healthcare. The Health Center provides a full range of acute care services to residents of Coles County and the surrounding eight counties. Home health services extend to the surroundings 19 counties in East Central and Southern Illinois. Active and consulting medical staffs include approximately 175 providers representing 28 specialties. Some of the services provided by the Health Center include: a Regional Cancer Center, a Heart Center with Cardiac Catheterization and Rehabilitation in partnership with Prairie Heart Institute of Illinois, a Surgery Center, Women & Childrens Services, a Level II Perinatal Unit, Medical-Surgical units, Behavioral Health Services, Close Observation Unit, a Sleep Disorders Center, Diagnostic Imaging Services, and Laboratory. Outreach services include a durable medical company (Lincolnland Home Medical Equipment), a Reference Laboratory, Peace Meal, Lincolnland Home Health and Hospice, Lifeline, and Lincolnland Homemakers. Sarah Bush Lincoln has 14 extended campus primary care locations and three walk-in clinics. Employing about 2,350 area residents, the Health Center promotes a culture of excellence through continuing personal and professional growth.
Institute For Diabetes Dscvry is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LifeGuard America is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.